Tolerability of nintedanib in patients with interstitial lung disease at our hospital and risk factors for discontinuation due to adverse events

Tolerability of nintedanib in patients with interstitial lung disease at our hospital and risk factors for discontinuation due to adverse events - Tolerability of nintedanib in patients with interstitial lung disease at our hospital and risk factors for discontinuation due to adverse events

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056059

Enrollment

131

Registered

2024-11-05

Start date

2023-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study included all patients who were prescribed nintedanib for interstitial lung disease at the respiratory medicine department of our hospital.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Duration of Nintedanib Administration	—

Countries

Japan

Contacts

Public ContactKotaro Kajiwara

Matsuyama Red Cross Hospital Department of Respiratory Medicine

respiratory24@outlook.jp0899241111

Outcome results